Imunon, Inc. (IMNN) stock
Close on Nov 12, 2026Market cap $3.57MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $3.57M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.36
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$14.64M
- EPS, diluted
- -$5.59
- Free cash flow
- -$14.18M
Trading
- Previous close
- $0.72
- Open
- $0.76
- Day's range
- $0.49 – $0.81
- Volume
- 2,190,007
- Average volume (20 days)
- 230,341
- Beta (5 years)
- 0.68
- 52-week range
- $0.68 – $4.38
- RSI (14 days)
- 30.0
- Volatility (1 year)
- 65.0%
- Relative volume
- 0.90×
- WACC
- 6.7%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | IMNN | S&P 500 | Difference | IMNN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -40.5% | -2.7% | −37.8 pts | ||
| 3 months | -60.4% | -1.7% | −58.7 pts | ||
| Year to date | -83.3% | +11.9% | −95.2 pts | ||
| 1 year | -83.9% | +12.0% | −95.9 pts | ||
| 3 years | -94.1% | +78.2% | −172.3 pts | -61.0% | +21.2% |
| 5 years | -99.6% | +73.2% | −172.8 pts | -66.1% | +11.6% |
| 10 years | -100.0% | +309.6% | −409.6 pts | -55.4% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Imunon filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Update
- Results
- Update
- Results
About Imunon
Pharmaceutical Preparations
Imunon, Inc. is a clinical-stage biotechnology company that creates treatments utilizing non-viral DNA technology to stimulate the human body's natural immunological responses against diseases. The company organizes its technology into two main modalities: TheraPlas, designed to encode proteins and cytokines to treat solid tumors, and PlaCCine, developed for viral antigen coding in infectious disease vaccine initiatives. Its lead clinical immunotherapy candidate, IMNN-001, delivers interleukin-12 locally to treat advanced ovarian cancer. Additionally, the company develops vaccine candidates, including a clinical-stage booster targeting COVID-19.
Company profile, executives and historyImunon stock: common questions
What is Imunon's stock price?
IMNN closed at $0.64 on Nov 12, 2026, down 11.57% on the day. Over the past 52 weeks it traded between $0.68 and $4.38.
What is Imunon's market cap?
Imunon was worth $3.57M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is IMNN's P/E ratio?
Imunon lost money over the twelve months to Mar 31, 2026 (diluted EPS -$5.59), so it has no meaningful P/E ratio.
Does Imunon pay a dividend?
No. Imunon has not paid a cash dividend over the last twelve months.
How has IMNN stock performed over the past year?
Including dividends, IMNN returned -83.9% over the past year, against +12.0% for the S&P 500.
How many IMNN shares are sold short?
0M shares were sold short at the latest FINRA report, 4.21% of the float, or 1.5 days of average trading volume.
Who are Imunon's competitors?
Companies most similar to Imunon by business, industry and size include PDSB, GOVX, INDP, PHIO, IMNM.
See a number that looks wrong?